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Recent advances in genomic sequencing and omics-based capabilities are uncovering tremendous therapeutic
opportunities and rapidly transforming the field of cancer medicine. Molecularly targeted agents aim to exploit key
tumor-specific vulnerabilities such as oncogenic or non-oncogenic addiction and synthetic lethality. Additionally,
immunotherapies targeting the host immune system are proving to be another promising and complementary
approach. Owing to substantial tumor genomic and immunologic complexities, combination strategies are likely to
be required to adequately disrupt intricate molecular interactions and provide meaningful long-term benefit to
patients. To optimize the therapeutic success and application of combination therapies, systematic scientific
discovery will need to be coupled with novel and efficient clinical trial approaches. Indeed, a paradigm shift is
required to drive precision medicine forward, from the traditional “drug-centric” model of clinical development in
pursuit of small incremental benefits in large heterogeneous groups of patients, to a “strategy-centric” model to
provide customized transformative treatments in molecularly stratified subsets of patients or even in individual
patients. Crucially, to combat the numerous challenges facing combination drug development—including our
growing but incomplete understanding of tumor biology, technical and informatics limitations, and escalating
financial costs—aligned goals and multidisciplinary collaboration are imperative to collectively harness knowledge
and fuel continual innovation.Background
The principle underlying combining therapeutic agents
is to maximize efficacy and overcome treatment resist-
ance by utilizing drugs with known activity, different
mechanisms of action, and minimally overlapping toxic-
ities. Cytotoxic chemotherapy combinations have had an
indispensable impact in oncology and malignant
hematology. Indeed, almost all curative cytotoxic regi-
mens consist of combination agents [1]. Many of these
combinations were discovered in a “trial and error” or
empirical manner, often with limited nonclinical data of
synergism.
In the past two decades, our growing genomic know-
ledge underlying oncogenesis has shifted the focus of
developmental therapeutics to molecularly targeted
agents (MTAs). This shift is coupled with advances and* Correspondence: lillian.siu@uhn.ca
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other novel molecular techniques such as transcriptome
analysis, RNA interference screening, and genome-
editing tools. MTAs aim to optimize the therapeutic
index by exploiting key tumor-specific vulnerabilities
such as oncogenic or non-oncogenic addiction and syn-
thetic lethality (Box 1). However, substantial genomic
complexity exists, such that tumors are rarely reliant on
one molecular aberrant pathway for survival, which, with
a few notable exceptions, limits the efficacy and durabil-
ity of response to single agent MTAs [2–4]. Beyond
MTAs, immuno-oncology agents have produced impres-
sive and durable tumor responses by reactivating host
immunity and are approved for a growing number of in-
dications, with combined immuno-oncology therapy
showing enhanced antitumor activity in some cases
[5–11]. Furthermore, emerging evidence suggests an
interplay between the tumor genomic landscape and
immune response, providing a rationale for the thera-
peutic integration of immune-based and genomically
based strategies [12–17].le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Box 1. Glossary terms (in order of appearance in text)
Therapeutic index: This describes the margin of safety of a drug.
It is defined as the ratio of the dosage of a
drug that produces toxicity in 50 % of
subjects to the dose that produces the
desired treatment effect in 50 % of subjects
(TD50/ED50). Drugs with narrow or low
therapeutic index are drugs with small
differences between therapeutic and toxic
doses.
Oncogene addiction: A concept describing the dependence of
cancer cells on the activity of an oncogene
for survival. The inhibition of the oncogene
may lead to cell death or arrest. For example,
the BCR-ABL fusion oncogene, targeted by
imatinib, is a major driver of tumorigeneis in
chronic myelogenous leukemia [2].
Non-oncogene
addiction:
Aside from oncogenes, tumorigenesis is
reliant on a range of other genes and
pathways. These non-oncogenes may be
exploited as drug targets. An example is
antiangiogenic therapy using VEGF inhibitors
in renal cell carcinoma.
Synthetic lethality: Two genes are said to be synthetically lethal
if simultaneous loss of function of both
genes results in cellular death but the loss
of function of either gene leads to a viable
phenotype. An example is the selective
susceptibility to PARP inhibition in
BRCA1/BRCA2-deficient cells [126].
Combination index: This quantitatively describes combination
drug interactions, where a combination
index (CI) < 1 indicates a greater effect than
the expected additive effect (synergism),
CI = 1 indicates a similar effect (additive), and
CI > 1 indicates a lesser effect (antagonism).
Umbrella trial: Genotype-based clinical trials testing different
drugs matched to molecular aberrations in a
single cancer type. An example is the
Lung-MAP trial (NCT02154490) in patients
with squamous non-small cell lung cancer,
which investigates multiple therapies
matched to specific molecular aberrations.
Basket trial: Genotype-based clinical trials testing one or
more drugs targeting one or more molecular
aberrations in a variety of cancer types. A
single trial may involve multiple cohorts,
which are generally defined by cancer type.
An example is a clinical trial of vemurafenib,
a BRAF inhibitor in multiple non-melanoma
cancers with BRAF V600 mutations [127].
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are needed for MTAs and immuno-oncology agents to
adequately disrupt intricate molecular and immune in-
teractions to provide long-term clinical benefit. However,
progress in this field is hampered by a multitude of chal-
lenges. Foremost among these is the rational selection of
combinations in the perplexing and dynamic disease
context, which is characterized by tumor genomic re-
dundancy and adaptability and considerable intra- andinter-patient heterogeneity [18, 19]. Secondly, clinical
trial methodology is not optimized for the evaluation of
MTA and immuno-oncology combinations and novel
approaches are urgently needed. Thirdly, concerted ef-
forts from regulatory authorities, investigators, and
pharmaceutical companies are crucial to enable efficient
drug discovery and development.
This review summarizes some of the past successes
and failures in the development of combination therap-
ies, explores the obstacles ahead, and suggests future di-
rections to manage the evolving dynamics of cancer.
Past and present status of combination drug
development
Types of MTA combinations
MTAs can be combined to inhibit multiple components
within a signaling network to evade resistance mecha-
nisms or to target distinct and potentially complemen-
tary oncogenic processes. Combination strategies may
include (1) additive or synergistic drug combinations of
the same mechanism or connected mechanisms of ac-
tion, (2) synthetic lethality pairings, and (3) the addition
of a second agent with a different mechanistic activity to
reverse resistance mechanisms. In addition, MTAs can
be combined with other therapeutic modalities, such as
radiotherapy, chemotherapy, and immuno-oncology
therapy. Table 1 demonstrates some examples of these
approaches.
Approved MTA combinations
Between January 2006 and June 2016, four MTA–MTA
and four MTA–endocrine-therapy combinations were
approved by the US Food and Drug Administration
(FDA) for use in adult solid malignancies, compared
with approximately 40 approved single-agent MTAs and
approximately 20 MTA–chemotherapy combinations
(Table 2) [20, 21]. These combination approvals are
based on randomized phase III or phase II trial data
demonstrating improved progression-free survival or
overall survival compared with the established standard
of care, which is almost always one of the agents in the
combination with or without chemotherapy [22–30]. In
all cases, one or both drugs were FDA approved prior to
being approved as a combination for the same disease
indication.
In addition to the MTA–MTA and MTA–endocrine-
therapy combinations, ipilimumab and nivolumab are
two immuno-oncology agents also approved as a doublet
regimen. Rather than targeting aberrant genomic path-
ways, these monoclonal antibodies (mAbs) inhibit im-
mune regulatory checkpoints, cytotoxic T-lymphocyte-
associated antigen 4 (CTLA-4) and programmed cell
death protein-1 (PD-1), respectively, producing durable
tumor regression in multiple tumor types [5–11].
Table 1 Types of combinations
Types of combinations Examples
(1) Synergistic or additive combinations
Targeting the same molecule for maximal target inhibition Dual human epidermal growth factor receptor 2 (HER2) blockade
(pertuzumab and trastuzumab in HER2-amplified breast cancer) [23, 25]
Vertical targeting: inhibiting two or more targets along the same pathway BRAF and MEK inhibition (vemurafenib and cobimetinib, dabrafenib,
and trametinib in melanoma) [27, 29]
Horizontal targeting: inhibiting parallel or compensatory pathways Phosphoinositide 3-kinase (PI3K) and MEK inhibition (BKM120 and
trametinib in RAS- or BRAF-mutant solid tumors) [128]
(2) Synthetic lethality Poly(ADP-ribose) polymerase (PARP) inhibitor and DNA-damaging agent
(veliparib plus platinum-based chemotherapy in triple-negative breast
cancer) (NCT02032277)
(3) Reversal of resistance Cyclin-dependent kinase (CDK) and estrogen receptor (ER) inhibition
(palbociclib and fulvestrant in hormone-receptor-positive breast cancer
in postmenopausal women) [30]
Table 2 FDA approvals of MTA or immuno-oncology combinations in adult solid tumors between January 2006 and June 2016 [20]
Year of approval Tumor type Combinationa Biomarker(s)
2016 RCC Lenvatinib + everolimusb
2016 Breast Palbociclib + fulvestrantb HR positive, HER2-negative
2015 Squamous NSCLC Necitumumab + cisplatin/gemcitabine
2015 Melanoma Cobimetinib + vemurafenibb BRAF V600 mutation
2015 Melanoma Nivolumab + Ipilimumabb
2015 CRC Ramucirumab + FOLFIRI
2015 Breast Palbociclib + letrozoleb HR positive, HER2-negative
2014 NSCLC Ramucirumab + docetaxel
2014 Ovarian, fallopian tube,
primary peritoneal
Bevacizumab + paclitaxel, liposomal doxorubicin or topotecan
2014 Cervix Bevacizumab + paclitaxel/cisplatin or paclitaxel/topotecan
2014 Gastric/GE junction Ramucirumab + paclitaxel
2014 Melanoma Trametinib + dabrafenibb BRAF V600 mutation
2012 CRC Ziv-aflibercept + FOLFIRI
2012 Breast Everolimus + exemestaneb HR positive, HER2-negative
2012 CRC Cetuximab + FOLFIRI KRAS wild type
2012 Breast Pertuzumab + trastuzumab and docetaxelb HER2 amplified/protein overexpression
2011 SCCHN Cetuximab + platinum/fluoropyrimidine
2010 Gastric/GE junction Trastuzumab + cisplatin/fluoropyrimidine HER2 protein overexpression
2010 Breast Lapatinib + letrozoleb HER2 amplified/protein overexpression
and HR positive
2009 RCC Bevacizumab + interferon-α
2008 Breast Bevacizumab + paclitaxel HER2 negative
2007 Breast Lapatinib + capecitabine HER2 amplified/protein overexpression
2006 Breast Trastuzumab + AC–T HER2 amplified/protein overexpression
2006 NSCLC Bevacizumab + platinum-based chemotherapy
2006 CRC Bevacizumab + fluoropyrimidine-based chemotherapy
2006 SCCHN Cetuximab + radiation
aExpanded indications in the same tumor type are not listed again in this table
bMTA–MTA, MTA–endocrine therapy or immuno-oncology–immuno-oncology combinations
AC–T doxorubicin/cyclophosphamide–paclitaxel, CRC colorectal cancer, FOLFIRI fluorouracil/leucovorin/irinotecan, GE gastro-esophageal, HR hormone receptor,
MTA molecularly targeted agent, NSCLC non-small-cell lung cancer, RCC renal cell carcinoma, SCCHN squamous cell carcinoma of the head and neck
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demonstrated enhanced treatment efficacy by targeting
non-redundant immune pathways [31, 32].
The scientific basis of these nine FDA-approved com-
binations is founded on proof of resistance mechanisms
to an established therapy and/or evidence of synergistic
or additive activity in animal models [28, 33–42]. The
targeting of the mitogen-activated protein kinase
(MAPK) pathway at two key levels is an example of
using dual targeted therapy to effectively counteract
genetic escape mechanisms. In the treatment of ad-
vanced malignant melanoma, combined inhibition of
BRAF and its downstream effector MAPK kinase
(MEK) led to improved survival outcomes compared
with BRAF inhibition alone. The doublet regimen
prevents MAPK pathway activation, which is the most
common mechanism of acquired resistance to BRAF
inhibitors [27, 29, 38, 39, 43, 44]. Notably, in these
nine approved combinations, MTAs are used at or
near their single-agent recommended dose, without
substantial increase in toxicity. Additionally, in seven
out of the nine combinations—with the exceptions of
lenvatinib and everolimus, and nivolumab and ipili-
mumab—established predictive biomarkers are utilized
for molecularly based patient selection [22–30].
Lessons learnt from unsuccessful MTA combinations
Approximately 75 % of investigational oncology com-
pounds that enter clinical testing do not ultimately re-
ceive regulatory approval; these include 50 % of drugs
tested in the phase III setting [45]. In most of these
cases, investigators could not have predicted the negative
results, and explanations for the lack of efficacy are often
deficient. In Table 3, we highlight some of the potential
reasons underlying past failed drug combinations.
Failure to show benefit at the phase III stage is par-
ticularly disappointing during drug development given
the immense financial cost and human resources in-
volved. Importantly, a large number of patients may have
been exposed to harm or unnecessary treatment. An
example is the combination of anti-epidermal growth
factor receptor (EGFR) antibodies (cetuximab or panitu-
mumab), anti-vascular endothelial growth factor (VEGF)
antibody (bevacizumab), and chemotherapy in metastatic
colorectal cancer. Both anti-EGFR and anti-VEGF mAbs
have established antitumor activity in combination with
chemotherapy in this setting [46–48]. A large body of
nonclinical data demonstrated synergism produced by
combined EGFR and VEGF blockade and a small phase
II study in irinotecan-refractory patients demonstrated
clinical benefit [49–51]. However, in two phase III trials,
which together included over 1700 patients, the addition
of cetuximab or panitumumab to bevacizumab and
chemotherapy in the frontline setting unexpectedlyresulted in significantly shorter progression-free survival,
including in the KRAS wild-type subpopulation, and tox-
icity was also increased [52, 53]. The reasons behind this
discouraging outcome are not known. Discontinuation
rates secondary to toxicity were similar in both arms
in one study [53]. The investigators postulated that
unfavorable pharmacokinetic and pharmacodynamic
interactions between the anti-EGFR and anti-VEGF
antibodies may have occurred, leading to the blunting
of the therapeutic effect of each agent [52, 53]. This
example serves as a reminder that although combin-
ing drugs with proven mechanisms of action is an at-
tractive and logical strategy, carefully designed early
clinical trials with comprehensive pharmacokinetic
and pharmacodynamic parameters are essential to
understand drug interactions and to provide proof of
concept.
Nonclinical development
Selecting and prioritizing combinations: a systematic
approach to drug discovery
Currently, there are approximately 100 approved anti-
cancer drugs and, according to the Pharmaceutical
Research and Manufacturers of America’s 2015 report,
approximately 1200 new anticancer drugs are in devel-
opment in the United States, amounting to approxi-
mately 845,000 possible pairings and an exponential
number of higher-order combinations [54]. This, in
addition to the expanding number of potential drug tar-
gets, necessitates systematic and efficient methods of
drug discovery.
Increasingly, industry and academia are utilizing
various methods of high-throughput screening, which le-
verage laboratory automation to simultaneously assay
the biological activities of a vast number of compounds
[55–59]. Indeed, unbiased chemical screening may un-
cover unexpected interactions, likely attributable to pre-
viously unknown interconnected cellular signaling
pathways [60, 61]. For example, in an attempt to identify
therapeutic partners for the Bruton’s tyrosine kinase
(BTK) inhibitor ibrutinib, a high-throughput screen
study in diffuse large B-cell-lymphoma cell-line models
demonstrated impressive combinatorial activity with a
range of mechanistically distinct drug classes, which
may warrant further investigation [55]. Additional
technological advances include in silico modeling
methods to facilitate large-scale genome-wide identifica-
tion of candidate synthetically lethal genes as new drug
targets and to predict drug response [62]. Computational
network-based algorithms can also systematically analyze
gene regulatory and signaling pathways to mechanistic-
ally define genetic determinants of disease and establish
new therapeutic targets [63]. Furthermore, ex vivo test-
ing in cell culture models derived from patient samples
Table 3 Challenges of combination drug development and examples of unsuccessful combinations
Challenges Examples
Target validity and engagement • Discordance between nonclinical and clinical data
• Difficulty characterizing biological relevance and
functionality of the target(s), target engagement
and modulation by the investigational agent(s),
and pathway interactions due to absent or poorly
designed pharmacodynamics studies in early
clinical studies
Selumetinib (MEK inhibitor) + MK-2206 (AKT inhibitor)
in metastatic CRC (phase II)
• Promising nonclinical data
• Target inhibition not consistently reached
• Other potential reasons for failure include possible
activation of compensatory mechanisms and
overlapping toxicities [129]
Pharmacological effect of drug
combination
• Effect of drug combinations, which may be additive,
synergistic, or antagonistic, has a direct impact on
antitumor activity and toxicity
• Often poorly understood in both nonclinical and
clinical environments
Adjuvant tamoxifen + anthracycline-based chemotherapy
in breast cancer found to be inferior to sequential
tamoxifen following chemotherapy (phase III)
• Antagonistic effect suggested by nonclinical data
[130, 131]
Patient selection • Being able to accurately select the subgroup of
patients who would derive maximal benefit can
substantially broaden the therapeutic window.
However, identification, validation, and
standardization of predictive biomarkers remain
very difficult
IMC-A12, R1507 or CP-751,871 (IGF-1R inhibitors) +
erlotinib (EGFR inhibitor) in metastatic NSCLC in three
separate trials (phase I/II, phase II and phase III,
respectively)
• Promising nonclinical data
• Three negative studies with limited activity in
unselected patients
• No biomarker identified from the studies
• Also poor tolerance seen [132–134]
Toxicity • Poor drug tolerance affects the maintenance of dose
intensity and duration, thereby limiting efficacy,
particularly if two agents share the same target or
have overlapping side effects
• Small-molecule TKI combinations may be more likely
than mAb combinations to cause increased off-target
toxicities and pharmacokinetic interactions via the
cytochrome P450 system [65]
Four phase I studies
• Ipilimumab (CTLA-4 inhibitor) + vemurafenib
(BRAF inhibitor) led to hepatotoxicity [135]
• Tremelimumab (CTLA-4 inhibitor) + sunitinib
(VEGFR inhibitor) led to renal toxity [136]
• Bevacizumab (VEGF inhibitor) + sunitinib led to
vascular/hematological toxicities [137]
• Temsirolimus (mTOR inhibitor) + sunitinib led to
skin/hematological toxicities [138]
CRC colorectal cancer, mAb monoclonal antibody, NSCLC non-small-cell lung cancer, TKI tyrosine kinase inhibitor
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and predictive tumor models than existing models for
therapeutic testing [64].
Complementary to these novel approaches, data-
sharing efforts are imperative to promote scientific col-
laboration. Examples include publically available data re-
positories that catalogue protein–protein interactions
and biological pathways such as Pathway Commons and
Database of Interacting Proteins [65, 66]. The US
National Cancer Institute (NCI) recently launched
Genomic Data Commons, an interactive data-sharing
platform enabling the import and harmonization of gen-
omic data from multiple research programs using stan-
dardized bioinformatics pipelines [67, 68]. Additionally,
large annotated cell-line drug-screen libraries, such as
the Cancer Cell Line Encyclopedia, Genomics of Drug
Sensitivity in Cancer Project, and NCI60 (the US
National Cancer Institute 60 human tumor cell line anti-
cancer drug screen), are publically accessible datasets
correlating drug sensitivity with detailed genomic data
and thus serve as rich resources for researchers [69–74].
Quality of nonclinical data
Nonclinical studies of drug combinations often report syn-
ergy without appropriate evaluation of the combinationindex (Box 1) [75]. Additionally, low rates (11–25 %) of re-
producibility of published laboratory data, including those
from high-impact journals, have been identified, despite at-
tempts to recreate the experimental environment, suggest-
ing limitations in the validity of scientific findings and
probable publication bias [76, 77]. Improving the reliability
and predictive value of nonclinical studies is fundamental
to successful clinical translation. Box 2 outlines important
issues to consider when designing the aims, experimental
conditions, and parameters of nonclinical studies. At a
minimum, benchmarks for nonclinical studies prior to
consideration of clinical testing should include validation
of a robust scientific hypothesis via demonstration of
mechanism of action, observation of objective synergistic
or additive antitumor activity, and acceptable safety at clin-
ically achievable drug concentrations.
Clinical development
In response to the fundamental challenges of tumor mo-
lecular diversity and the expanding portfolio of novel
MTA and immuno-oncology agents, clinical trial designs
and statistical approaches are evolving to optimize the
evaluation of combination therapeutics and streamline
their clinical development. Despite considerable progress,
more innovative precision medicine-based approaches are
Box 2. Suggestions for improving the quality of nonclinical studies
Suggestions Benefits
Use multiple cell lines and animal models with molecular
characterization
To recapitulate tumor heterogeneity and the influence of host effects
Characterize pharmacokinetic and pharmacodynamic
interactions
To reach an understanding of the interactions between drugs, their
targets, and the downstream effects
Study optimal concentration and exposure of each drug
for target engagement
To inform the dosing ratio and schedule to be explored in clinical trials
Identify biomarkers to be further explored and refined
in early phase trials
To assist with patient selection or stratification
Set a predetermined benchmark prior to contemplating
clinical testing
To reduce the chance of futile clinical trials
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to bring truly durable benefit for molecularly stratified
subsets of patients or even for individual patients.
Novel dose-finding strategies
Traditional rule-based dose-escalation trial designs,
which rely on the premise of dose-dependent toxicity,
may have considerable limitations in defining the bio-
logical optimal dose and schedule of combination MTAs.
Unlike cytotoxic chemotherapy, the relationship between
dose, toxicity, target inhibition, and efficacy is less pre-
dictable with MTA therapy [78]. Pharmacological inter-
actions of drug combinations can also impact on dose
effect. Furthermore, the assessment of dose-limiting tox-
icity (DLT), a key determinant of the maximum tolerated
dose (MTD) and the recommended phase II dose, can
be problematic for phase I MTA trials. The traditional
DLT window of observation—typically the first cycle of
treatment—used in trials of cytotoxic agents may not be
adequate, as MTAs may display delayed toxicity due to
their relatively long half-life and chronic dosing sched-
ule. There is also a lack of consensus on the definitions
of DLT, and these have been found to be widely
heterogenous across MTA clinical trials [79].
Adaptive Bayesian model-based designs may be better
placed to cater for the complex variables associated with
combination MTAs, by incorporating pre-study prob-
ability of toxicity and updating such probability with
real-time adverse event data to inform dose-escalation
decisions [80–83]. In simulation studies, adaptive de-
signs were found to maximize the number of patients
treated at or near the MTD compared with rule-based
designs [84, 85]. Importantly, adaptive designs allow pro-
spective modifications on aspects of the trial as the data
evolve, offering greater flexibility to researchers. Add-
itionally, multiple methods have been proposed using
both toxicity and efficacy as endpoints [86–88]. For ex-
ample, the zone method describes a parallel phase I/II
design that uses initial rule-based dose escalation andsubsequent Bayesian adaptive randomization to enable
simultaneous evaluation of the safety and efficacy of
multiple dose combinations, such that sample size can
be reduced and more patients are treated with the
higher-efficacy dose levels [86]. However, one challenge
of adaptive designs is the requirement for continual bio-
statistical modeling, which may have affected their up-
take in the past, although the application of these
designs is increasing with time [84, 89, 90]. An oper-
ationally hybrid approach is the modified toxicity prob-
ability interval design, which obviates the requirement
for computational modeling by utilizing an up-and-
down dose-assignment scheme conceptually similar to a
rule-based algorithm but guided by Bayesian models
[91, 92]. This design has been used in a number of
phase I clinical trials [93, 94].
Currently, there is no preferred dose-escalation design
for combination MTAs. The choice of the most appropri-
ate dose schedule selection and dose-finding method
should be informed by knowledge of the nonclinical and
clinical pharmacology of the agents of interest and based
on consultation between experienced clinical researchers,
sponsors, and statisticians. Comprehensive pharmacoki-
netic evaluation and pharmacodynamic assessment of tu-
mors in early phase trials are vital to assess for target
modulation and to mechanistically characterize on- and
off-target toxicities. These are particularly pertinent in
combination studies to delineate individual drug effects
and to evaluate pharmacological interactions. Multiple tar-
gets may also need to be cross-examined to assess network
inter-dependencies in identifying resistance mechanisms.
Integrating the immune landscape
Combinations of novel immune checkpoint and co-
stimulatory molecules are actively being evaluated for
additive or synergistic effects. Additionally, as multiple
oncogenic pathways can foster immunosuppressive
microenvironments, immuno-oncology agents are also
being investigated in combination with MTAs, with
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dictive biomarkers are presently lacking, emerging im-
mune monitoring techniques are giving insights into the
interactions between tumor antigen profiles, the micro-
environment, and the immune response, guiding poten-
tially personalized immuno-oncology strategies [95].
However, the unique properties of immunotherapies
present multiple challenges to clinical trial design, de-
manding careful forethought on dosing and schedule
decisions, patient selection, toxicity assessment, phar-
macokinetic/pharmacodynamic monitoring, and choice
of endpoints. For example, immuno-oncology agents
often do not reach a MTD in dose-escalation studies
and exhibit distinctive patterns of tumor response and
immune-related toxicities, which are not necessarily
dose-dependent. Furthermore, nonclinical studies of
immuno-oncology agents are technically difficult
owing to species-specific differences in immune re-
sponse and the lack of reliable models [96].
Improving the efficiency of drug development: a shift
from the traditional three-phase approach
The desire to expedite drug development has challenged
the conventional three-phase clinical trial paradigm, in
which safety and efficacy objectives are mandated at
each distinct stage to fulfill regulatory requirements. In-
deed, the time period from first-in-human testing to
regulatory approval for oncology drugs typically aver-
aged 7–9 years, substantially longer than agents of other
therapeutic classes [45, 97]. Novel designs including
seamless phase I/II, II/III clinical trials and large dose-
expansion cohorts in phase I trials are increasingly uti-
lized to streamline clinical development, obviating
lengthy pauses between trials [98–100]. For example, the
anti-PD-1 mAb pembrolizumab received accelerated ap-
proval by the FDA in September 2014 for use in meta-
static melanoma, based on efficacy data from 173
patients enrolled onto the expansion cohort of a phase
Ib trial (KEYNOTE-001), a mere 3 years after clinical de-
velopment began [8]. Dose-expansion cohorts are often
conducted in phase I trials for anticancer agents given
alone or in combination that demonstrate compelling
early signals of activity. These “tails” in phase I trials,
typically in the form of disease-specific or biomarker-
specific cohorts, apply intermediate endpoints, such as
objective response rate, to support accelerated approval
[99]. However, the use of these strategies requires clearly
defined goals, pragmatic protocols, and statistical design
with the flexibility to respond to evolving data and ob-
jectives, independent oversight, and a commitment from
researchers, commercial sponsors, and regulators to
work in tandem [99]. Getting these factors right is im-
portant to strike a balance between protection of patient
safety and interests and therapeutic innovation.Targeting tumor heterogeneity: genomically informed
clinical trial designs and biomarker development
Multiple umbrella (histology-specific) and basket
(histology-agnostic, aberration-specific) clinical trials
are currently ongoing, incorporating genomic testing
results for treatment assignment to genotype-matched
therapies and combinations (Lung-MAP, NCT02154490;
BATTLE, NCT00409968; NCI-MATCH, NCT02465060;
and My Pathway, NCT02091141) (Box 1) [101]. The size
and scope of these umbrella and basket trials can vary
based on complexities and heterogeneities of tumor geno-
types under evaluation. In some cases, adaptive Bayesian
model-based designs can be embedded in these clinical
trials to dynamically test multiple hypotheses, doses and
schedules (Fig. 1). The adaptive design allows prospective
decisions to be made based on accumulating results that
become available during the course of the trial, such that
more patients can be enrolled in cohorts showing the
strongest efficacy signals and poorly performing cohorts
can be closed early; and additional treatment cohorts test-
ing novel agents and combinations may also be added. Al-
though the clinical utility of genotype-matched trials
remains to be proven, they provide a framework to effi-
ciently probe the relationship between molecular aberra-
tions, tumor histology, and MTA activity. Genotype-based
trials may also be distinctly advantageous in matching tar-
geted treatments for patients with low prevalence muta-
tions, although extensive screening efforts or parallel
molecular screening programs will be required to identify
these patients. The establishment of national or inter-
national registries of patients whose tumors have under-
gone molecular profiling that enables rapid identification
of rare genotypes might be useful. An additional challenge
is that most of these molecularly based clinical trials rely
on genomic sequencing data from a single tumor sam-
ple, offering only a static “snapshot” of patients’ gen-
omic profiles. Cancer Research UK’s TRACERx trial
sets a precedent for a prospective non-interventional
study using multiregional and longitudinal tumor and
circulating biomarker sampling to map the impact of
dynamic intra-tumor heterogeneity during the course of
disease progression. Insights gained from this study will
inform the future development of dynamic therapeutic
genomic trials [102].
To support molecular-based patient selection strategies,
biomarker development and validation are crucial, prefer-
ably in concert with drug discovery and testing. A success-
ful example is the development of crizotinib in anaplastic
lymphoma kinase fusion gene (ALK)-translocated non-
small cell lung cancer, in which the identification of a mo-
lecular subset of patients helped accelerate drug registra-
tion [4]. The currently ongoing I-SPY 2 (NCT01042379)
is an adaptive multi-cohort trial for locally advanced
breast cancer, aiming to identify biomarker-matched
Intermittent dosing of 1 drug
Other therapeutic
strategies










Continuous dosing of both drugs













Fig. 1 An example of an adaptive trial design. Patients are matched to treatments according to molecular subtype. Multiple doses and schedules
are tested in dose escalation for the combination of drugs A and B. Adaptive randomization can be used to maximize the number of patients
randomized to the most effective arm. Schedules that show inferior activity, inferior pharmacokinetic/pharmacodynamic profiles, or increased
toxicity are stopped early (red crosses) and the most optimal dose/schedule is taken forward to cohort expansion. IO immuno-oncology, PD
pharmacodynamics, PK pharmacokinetics
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therapies have demonstrated improved activity compared
with standard therapy in distinct biomarker signature pop-
ulations and have met pre-specified criteria for testing in
confirmatory phase III trials [103–105]. In a recent review,
biomarkers that aid patient selection were found to im-
prove the phase transition probabilities of oncology drugs,
although the majority of non-orphan drugs are still being
developed without markers [106]. The US Institute of
Medicine has released ten recommendations for the
clinical development and use of biomarker tests, in recog-
nition of the wide-ranging obstacles in the context of
tumor heterogeneity, substantial technical difficulties in
assay reproducibility and standardization, and reimburse-
ment barriers [107]. Challenges notwithstanding, drug–
biomarker pairing is vital to enhance the therapeutic index
of MTAs and bring maximal benefit to the appropriate
target population.
Precision medicine: the individualized dynamic model
In addition to spatial tumor heterogeneity, there is in-
creasing awareness of tumor clonal evolution as a key
mechanism of therapeutic failure, whereby genomic and
epigenetic alterations and resistant variants develop and
proliferate under selective treatment pressures [108, 109].Thus, effective precision medicine would need not only to
respond to the molecular diversity unique to each individ-
ual patient but also to adapt to the evolving dynamics of
cancer. The individualized dynamic model may be a solu-
tion to this complex challenge, allowing intelligent drug
combinations to be tailored to the genomic and immune
profile of individual patients. Critical to this approach is
the longitudinal monitoring of the changing molecular
landscape to assess for treatment efficacy, to enable the
early discovery of emerging resistant clones, and to target
these pre-emptively with new drugs or combinations prior
to the onset of clinical or radiological progression.
To facilitate the collection of dynamic molecular infor-
mation, novel techniques such as serial measurements of
circulating tumor DNA (ctDNA) or cell-free DNA
(cfDNA) can be used at key treatment time points or
regular intervals and present a less invasive alternative
to tumor biopsies [110, 111]. A recent study of serial
cfDNA sampling utilizing next-generation sequencing in
phase I patients demonstrated the feasibility of this ap-
proach and suggested that cfDNA allele frequency dy-
namics may correlate with clonal response to targeted
therapy [112]. Moreover, a number of other approaches
are showing early promise to assist with dynamic thera-
peutic monitoring and prediction of specific treatment
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using patients’ own avatars for drug sensitivity testing
may help to predict the emergence of resistance clones
ex vivo and inform therapeutic options, although clinical
application requires successful engraftment and timely
generation of models [113, 114]. The use of patient-
derived organoids may provide a suitable alternative with
a faster turnaround time. Emerging radiomic techniques,
which enable high-throughput extraction of a large
number of quantitative features from imaging modalities
(computed tomography (CT), positron emission tomog-
raphy (PET), or magnetic resonance imaging (MRI)),
bring hope of providing noninvasive methods to track
phenotypic changes in anatomical imaging during treat-
ment, and associations with underlying gene expression
patterns have been shown [115, 116].
The proposed individualized dynamic model offers the
compelling potential to deliver immediate and durable
benefit to patients, as well as an opportunity to study
disease evolution and biology at an individual genetic
level. However, the implementation and scaling-up of
this approach may face a myriad of technical, resource,
and culture issues. In Table 4, key considerations in
designing and executing dynamic genomics trials are
highlighted. Figure 2 presents an example of an individu-
alized dynamic trial design.Table 4 Key components of individualized dynamic studies
Key components Comments
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A review of the characteristics of combination clinical
trials listed on ClinicalTrials.gov between 2008 and 2013
found that 25.6 % of oncology trials were combination
trials and, surprisingly, the ratio of combination trials to
all trials decreased over time (p < 0.05), from 29.5 % in
2008 to 22.7 % in 2012. Furthermore, trials supported by
the US National Institutes of Health are significantly
more likely to use combinations than those supported
by industry [117]. Barriers to industry investment and
collaborations in combination therapy may include con-
cerns regarding rising expenditure, intellectual property
protection, toxicity and risk attribution, profit implica-
tions, and more complex regulatory pathways. However,
industry alliances are vital to maximize the access of ex-
perimental therapy for nonclinical and clinical evalua-
tions. Academia and cooperative groups may play a
central unifying role. The NCI, for example, launched
the Critical Molecular Pathways pilot project and devel-
oped template data sharing and intellectual property lan-
guage for combination studies [72, 118]. The Institute of
Medicine also sponsored a workshop to set standards on
the application of models of precompetitive collabor-
ation to align competing goals and facilitate industry-
wide productivity [119]. Precompetitive collaboration re-
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Fig. 2 A proposed individualized dynamic study in colorectal cancer. Multiple hypotheses are tested in this parallel individualized dynamic
design. This hypothetical example is in colorectal cancer patients after progression on standard therapies. Baseline tumor characterization includes
whole-genome sequencing (WGS)/whole-exome sequencing (WES) and transcriptome sequencing from fresh tumor biopsies, circulating tumor
DNA (ctDNA) sampling, immune profiling, and radiomics analysis. Patient-derived xenografts (PDXs)/patient-derived organoids (PDOs) are also
generated. Drug therapy is then tailored to each patient’s mutational and immune profile. While on treatment, serial ctDNA sampling occurs 4
weekly and radiomics is performed every 8 weeks to guide therapeutic decisions. Patient one is used as an example: (1) at week 0, started on
programmed cell death protein-1 (PD-1) inhibitor and MEK inhibitor; (2) at week 12, treatment is changed to phosphoinositide 3-kinase (PI3K)
inhibitor and MEK inhibitor due to the increase in the allele frequency of a PIK3CA mutation; and (3) at week 20, the allele frequencies of both
PIK3CA and KRAS mutations continue to rise and treatment is changed to therapy informed by PDX/PDO data. CT computed tomography, mut
mutation, PD progressive disease, PR partial response, SD stable disease, wt wild type, MSI microsatellite instability, inh inhibitor
Day and Siu Genome Medicine  (2016) 8:115 Page 10 of 14burden of research tasks for mutual benefit, often in
early stages of product management, such as the devel-
opment of common infrastructure and aggregation of
data [119]. This may become a necessity in combination
drug development owing to increasing biological com-
plexity coupled with high rates of clinical failure. Add-
itionally, commercial incentives for collaboration to
develop combination treatments include the opportunity
to re-purpose and market unsuccessful drugs, while re-
ducing duplication of investigational pipelines. Recently,
inter-company and industry–academia partnerships seem
to have been invigorated, as evidenced by large genomi-
cally based trials such as NCI-MATCH, I-SPY 2, and
Lung-MAP and the AstraZeneca–Sanger Institute Drug
Combination Prediction DREAM Challenge [120].Cumbersome clinical trial operational systems can
substantially hinder and add to the cost of drug develop-
ment. A study found that opening a phase III coopera-
tive group trial required a median of 2.5 years from the
time of concept review by the cooperative groups to trial
opening at individual cancer centers [121]. The time to
activation—the period from when a trial is submitted for
consideration until it opens for enrolment—at cancer
centers was median 120 days (range 21–836 days) [121].
Moreover, a direct statistical relationship was found be-
tween lengthy trial development and poor accrual in a
linked study [122]. Thus, efforts should be directed at
re-engineering and simplifying current processes for trial
pre-activation, activation, and conduct, and, where
possible, using central infrastructure and eliminating
Day and Siu Genome Medicine  (2016) 8:115 Page 11 of 14overlapping administrative and logistical requirements
[123]. The Novartis Signature Program is an example of
a basket trial with no pre-designated study sites, which
utilizes a standard contract, budget, informed consent,
and ethics process to rapidly open the study at institu-
tions once a patient has been identified from local gen-
omic profiling results [124].
The limited utility of single agents provides the im-
petus to combine drugs early in their development, ra-
ther than delaying until one or both drugs is approved.
In recognition of this, the FDA published their guidance
on the co-development of two or more new investiga-
tional drugs in 2013, which emphasizes the need for a
biological rationale for early co-development and out-
lines recommendations for nonclinical and clinical
testing. It also provides direction for approval and mar-
keting processes, with an emphasis on encouraging early
and regular dialogue between commercial sponsors and
the FDA to streamline and purpose-fit their efforts
[125]. These guidelines will complement existing expe-
dited access programs—such as breakthrough designa-
tion, accelerated, and priority review—to assist with
efficient combination therapy development.
Conclusions
To adequately address the immense complexity and
heterogeneity underlying oncogenesis and disease pro-
gression, innovative combination strategies will need
to be customized to patients’ unique molecular and
immune profiles and adaptively applied to respond to
evolving changes over time. Moreover, in light of the
current pace of scientific discovery and mounting fi-
nancial costs, it is apparent that the existing frame-
work of oncological drug development, with substantial
attrition and lengthy timelines, is inefficient and ul-
timately unsustainable. Systematic high-throughput
methods and computational network-based platforms
can be utilized to explore novel therapeutic targets
and identify synergistic or additive drug combinations.
Clinical trial designs should be informed by compre-
hensive understanding of tumor biology and pharma-
cology and should leverage novel approaches to more
effectively investigate new drug combinations. Through-
out the nonclinical and clinical processes, co-development
of biomarkers must be prioritized to refine and optimize
patient selection. Importantly, meaningful collaborations
and coordination of efforts are crucial among all stake-
holders to collectively overcome technical, informatics,
and logistical challenges, toward the shared goal of preci-
sion medicine.
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